Biotech Intuition

Biotech Intuition

Download on the App Store

Biotech Intuition episodes

  • Daily - Nov 2, 2026

    Daily - Nov 2, 2-26 — Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    Chapters
    00:00 Today's Lead Biotech Stories
    00:27 FDA Grants Accelerated Approval to VOCERYQ
    00:53 INOVIO Confirmatory Trial and Launch Timeline
    01:10 Teva Halts Phase 2 TOPAS-MSA Trial for Futility
    01:37 Karyopharm Files Chapter 11 and Plans Ayrmid Merger
    02:00 Alligator Out-Licenses Mitazalimab to Biossil
    02:28 SEC Declares Chemomab-Scipher Merger S-4 Effective
    02:49 Samsung Biologics Advances PolyPeptide Group Buyout
    03:06 Enlivex Reports 12-Month Allocetra Topline Data
    03:28 Looking ahead
    04:01 SOZO Intuition

    Summary
    Today on the SOZO biotech daily, we track three major developments across the sector: INOVIO secures accelerated FDA approval for VOCERYQ in recurrent respiratory papillomatosis, Teva discontinues its Phase 2 study of emrusolmin in multiple system atrophy following an interim futility review, and Karyopharm Therapeutics enters Chapter 11 restructuring with plans to merge with Ayrmid. Sources are in the show notes.

    Sources by chapter

    Today's Lead Biotech Stories

    FDA Grants Accelerated Approval to VOCERYQ
    INOVIO receives FDA accelerated approval for VOCERYQ in recurrent respiratory papillomatosis 2026-11-02

    INOVIO Confirmatory Trial and Launch Timeline

    Teva Halts Phase 2 TOPAS-MSA Trial for Futility
    Teva to discontinue Phase 2 TOPAS-MSA study of emrusolmin after interim futility analysis 2026-11-02

    Karyopharm Files Chapter 11 and Plans Ayrmid Merger
    Karyopharm announces planned merger with Ayrmid under Chapter 11 restructuring 2026-11-02

    Alligator Out-Licenses Mitazalimab to Biossil
    Alligator Bioscience to sell mitazalimab rights to Biossil for $0.75 million upfront 2026-10-31
    Fresenius Kabi and WuXi Biologics sign exclusive biosimilars development agreement 2026-11-02

    SEC Declares Chemomab-Scipher Merger S-4 Effective
    Chemomab and Scipher Medicine S-4 registration statement declared effective 2026-11-02

    Samsung Biologics Advances PolyPeptide Group Buyout
    Samsung Biologics reports 97.66% provisional participation in PolyPeptide tender offer 2026-11-02

    Enlivex Reports 12-Month Allocetra Topline Data
    Enlivex reports 12-month Phase I/IIa Allocetra results in knee osteoarthritis 2026-11-02

    Looking ahead
    Mirum Pharmaceuticals presents Phase 3 brelovitug and Phase 2b volixibat data at AASLD 2026 2026-11-02

    SOZO Intuition

    5 min
  • Daily - Oct 30, 2026

    Daily - Oct 30, 2026 — Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    Chapters
    00:00 Today's Highlights
    00:55 Pelthos and Castle Creek to Merge Operations
    01:40 Merger Structure and D-Fi Development Plans
    02:15 China Grants Priority Review for Hengrui's ADC
    03:02 SHR-A1811 Met Primary Endpoint in Phase 3 Trial
    03:47 Moleculin Completes Dosing in Part A of MIRACLE
    04:24 MIRACLE Data Readout Slated for 2027
    04:48 CLINUVEL Files NEURACTHEL Instant in Europe
    05:15 Celularity Partners with Vesalius on Peptides
    06:04 Repligen Announces $1B Convertible Notes Offering
    06:40 Looking Ahead

    Summary
    Welcome to the SOZO biotech daily. Today we lead with a definitive merger agreement between Pelthos Therapeutics and Castle Creek Biosciences to establish a serious-skin-disease company centered on late-stage cell therapy, China’s priority review designation for Jiangsu Hengrui Medicine’s antibody-drug conjugate SHR-A1811 in advanced breast cancer, and Moleculin Biotech completing patient dosing in the initial stage of its registrational acute myeloid leukemia trial. Looking ahead, key developments to track include the initiation of the continued late-stage study for Castle Creek's lead gene-modified cell therapy, China's forthcoming regulatory decision on Hengrui's priority breast cancer submission, and Moleculin's upcoming data readout in 2027 to establish dose selection for the next phase of clinical evaluation. Sources are in the show notes.

    Sources by chapter

    Today's Highlights

    Pelthos and Castle Creek to Merge Operations
    Pelthos Therapeutics and Castle Creek Biosciences Agree to Merge Around a Phase 3 Dystrophic Epidermolysis Bullosa Program 2026-10-30

    Merger Structure and D-Fi Development Plans

    China Grants Priority Review for Hengrui's ADC
    China's NMPA Grants Priority Review to Hengrui's SHR-A1811 for HER2-Positive Breast Cancer 2026-10-29

    SHR-A1811 Met Primary Endpoint in Phase 3 Trial

    Moleculin Completes Dosing in Part A of MIRACLE
    Moleculin Completes Part A Dosing in Pivotal MIRACLE Trial of Annamycin in Relapsed or Refractory AML 2026-10-29

    MIRACLE Data Readout Slated for 2027

    CLINUVEL Files NEURACTHEL Instant in Europe
    CLINUVEL Files NEURACTHEL Instant Dossier with European Regulators 2026-10-29

    Celularity Partners with Vesalius on Peptides
    Celularity and Vesalius Longevity Labs Sign Exclusive U.S. Manufacturing Collaboration for Peptual Peptide APIs 2026-10-29

    Repligen Announces $1B Convertible Notes Offering
    Repligen Announces $1 Billion Private Convertible Senior Notes Transaction 2026-10-29

    Looking Ahead

    7 min
  • Biotech Daily Top Stories - October 22, 2026

    Daily - Oct 22, 2026 - Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    SUMMARY
    Welcome to the SOZO biotech daily brief. Today, our lead stories cover an FDA accelerated approval for AstraZeneca in primary immunoglobulin A nephropathy, mid-stage clinical trial results from Lumen Bioscience in Clostridioides difficile, and a multi-target miniprotein discovery alliance between Astellas Pharma and AI Proteins. We also follow pipeline progress from Newron Pharmaceuticals and Thiogenesis Therapeutics, alongside new venture backing for Reju Therapeutics. Sources are in the show notes.

    CHAPTERS AND SOURCES

    00:00 - SOZO Biotech Daily Brief

    00:34 - AstraZeneca's Ultomiris Wins FDA Accelerated Approval
    Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A…:
    https://www.astrazeneca.com/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html

    01:38 - Lumen Reports Phase 2 RePreve Results for LMN-201
    Lumen's LMN-201 shows positive RePreve Phase 2 results in C. difficile 2026-10-22:
    https://www.lumen.bio/2026/10/22/lumen-s-lmn-201-shows-positive-re-preve-results-in-c-difficile

    02:32 - Astellas and AI Proteins Form Miniprotein Discovery Pact
    Astellas Pharma and AI Proteins enter miniprotein discovery collaboration valued at over $400 million 2026-10-21:
    https://www.businesswire.com/news/home/20261021073833/en/AI-Proteins-Announces-Research-Collaboration-and-License-Agreement-With-Astellas-Pharma-to-Discover-and-Develop-Novel-Miniprotein-Based-Therapeutics-Valued-at-Over-%24400-Million

    03:18 - Newron Completes Phase 3 ENIGMA-TRS 1 Enrollment
    Newron completes enrollment of pivotal Phase 3 ENIGMA-TRS 1 study of evenamide 2026-10-22:
    https://www.newron.com/news-and-media/regulatory-news/newron-completes-enrollment-pivotal-phase-3-enigma-trs-1-study

    03:54 - FDA Clears TTI-0102 IND in Nephropathic Cystinosis
    Thiogenesis announces FDA clearance of IND for TTI-0102 in nephropathic cystinosis 2026-10-22:
    https://finance.yahoo.com/healthcare/articles/thiogenesis-announces-fda-clearance-ind-090000510.html

    04:29 - Nanjing Reju Therapeutics Closes Oversubscribed Series A
    Reju Therapeutics completes oversubscribed Series A financing 2026-10-21:
    https://www.vcbeathealth.com/article/63807

    04:57 - Looking ahead

    05:32 - SOZO Intuition

    6 min
  • Biotech Daily Top Stories - October 21, 2026

    Daily - Oct 21, 2026 - Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    CHAPTERS
    00:00 SOZO Biotech Daily Brief
    00:35 Fenebrutinib Cuts Relapse Rate in Multiple Sclerosis
    01:11 Fenebrutinib Slows Chronic Brain Lesion Progression
    01:46 Genentech Highlights Pediatric Ocrevus and Enspryng
    02:23 Miv-cel Shows 1-Year Mobility Gains in Stiff Person
    03:00 Miv-cel Enables Immunotherapy Freedom at One Year
    03:38 Oral Olorofim Meets Non-Inferiority in Aspergillosis
    04:12 Olorofim Reduces Renal Injury; Resubmission Planned
    04:48 FDA Approves ORLADEYO Oral Pellets for HAE
    05:30 LMN-201 Biologic Cocktail Succeeds in Phase 2 C. diff
    06:13 BIOX-101 Reduces Edema Growth in Brain Hemorrhage
    06:56 Servier Partners with Okomera on Tumor Miniaturization
    07:37 Looking ahead
    08:24 SOZO Intuition

    SUMMARY

    SOURCES BY CHAPTER

    SOZO BIOTECH DAILY BRIEF

    FENEBRUTINIB CUTS RELAPSE RATE IN MULTIPLE SCLEROSIS
    Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 2026-10-21:
    https://www.gene.com/media/press-releases/15139/2026-10-21/genentech-presents-new-pivotal-trial-data-across-broad-neuroimmunology-portfolio-at-mstoronto2026

    FENEBRUTINIB SLOWS CHRONIC BRAIN LESION PROGRESSION

    GENENTECH HIGHLIGHTS PEDIATRIC OCREVUS AND ENSPRYNG

    MIV-CEL SHOWS 1-YEAR MOBILITY GAINS IN STIFF PERSON
    Kyverna Therapeutics Presents Full One-Year Registrational Data Set Demonstrating Sustained Clinical Benefit of Miv-cel in Stiff Person Syndrome at MS Toronto…:
    https://www.globenewswire.com/news-release/2026/10/21/3385400/0/en/kyverna-therapeutics-presents-full-one-year-registrational-data-set-demonstrating-sustained-clinical-benefit-of-miv-cel-in-stiff-person-syndrome-at-ms-toronto.html
    Quell Therapeutics Advances QEL-005 to Second Dose Cohort in CHILL Phase 1/2 Trial in Rheumatoid Arthritis and Systemic Sclerosis 2026-10-21:
    https://www.biospace.com/press-releases/promising-early-safety-data-as-quell-therapeutics-advances-qel-005-a-novel-engineered-ntreg-therapy-to-second-dose-cohort-in-chill-phase-1-2-trial-in-difficult-to-treat-rheumatoid-arthritis-and-systemic-sclerosis
    Arctic Therapeutics Closes Oversubscribed US$21.5 Million Financing 2026-10-21:
    https://www.prnewswire.com/news-releases/arctic-therapeutics-closes-oversubscribed-us21-5-million-financing-302915211.html

    MIV-CEL ENABLES IMMUNOTHERAPY FREEDOM AT ONE YEAR

    ORAL OLOROFIM MEETS NON-INFERIORITY IN ASPERGILLOSIS
    Shionogi and F2G Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome Followed by Standard of Care in Invasive…:
    https://www.shionogi.com/global/en/news/2026/10/e20261021_3.html

    OLOROFIM REDUCES RENAL INJURY; RESUBMISSION PLANNED

    FDA APPROVES ORLADEYO ORAL PELLETS FOR HAE
    BioCryst Announces U.S. FDA Approval of ORLADEYO 150 mg Oral Pellets for Adults and Adolescents with Hereditary Angioedema 2026-10-21:
    https://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html

    LMN-201 BIOLOGIC COCKTAIL SUCCEEDS IN PHASE 2 C. DIFF
    Lumen Bio Reports Positive Phase 2 Results from the RePreve Clinical Trial of LMN-201 for C. difficile Infection 2026-10-21:
    https://www.prnewswire.com/news-releases/lumen-bio-reports-positive-phase-2-results-from-the-repreve-clinical-trial-lmn-201-for-c-difficile-infection-302915046.html

    BIOX-101 REDUCES EDEMA GROWTH IN BRAIN HEMORRHAGE
    Bioxodes BIOX-101 Phase 2a Data Show Statistically Significant Reduction in Perihematomal Edema Growth in Intracerebral Hemorrhage 2026-10-21:
    https://www.bioxodes.com/newsroom/press-releases/bioxodes-biox-101-phase-2a-data-show-statistically-significant-reduction-in-perihematomal-edema-growth-in-intracerebral-hemorrhage

    SERVIER PARTNERS WITH OKOMERA ON TUMOR MINIATURIZATION
    Okomera Announces a Commercial Agreement With Servier to Use Its Tumor Miniaturization Technology for Cancer Research 2026-10-21:
    https://www.okomera.com/_files/ugd/631ec0_f041bdf1df614649962c581bf1a5e735.pdf

    LOOKING AHEAD
    Akeso Announces Summit Therapeutics and ECOG-ACRIN Enter a Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer…:
    https://www.prnewswire.com/news-releases/akeso-announces-summit-therapeutics-and-ecog-acrin-cancer-research-group-enter-into-phase-iiiii-clinical-trial-collaboration-to-evaluate-ivonescimab-in-first-line-biliary-tract-cancer-302915469.html
    Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator MNA-001 in Alzheimer Disease 2026-10-21:
    https://www.prnewswire.com/news-releases/muna-therapeutics-announces-positive-phase-1-results-supporting-potential-of-oral-small-molecule-trem2-modulator-mna-001-in-alzheimers-disease-302914619.html
    Additional references omitted to fit YouTube's 5,000-character limit.

    9 min
  • Biotech Daily Top Stories - Oct 20, 2026

    Daily - Oct 20, 2026 v2 - Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    CHAPTERS
    00:00 Biotech Daily Briefing
    00:43 RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
    01:32 RAP-219 Validates Selective Mechanism in Acute Mania
    02:12 Casdatifan Shows Efficacy in Renal Cell Carcinoma
    03:02 Casdatifan Delivers 35-Month Median Overall Survival
    03:46 Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
    04:43 FDA Approves Process 2.0 for Alvotech's SIMLANDI
    05:27 Ambrose Acquires AM-Pharma for up to 161 Million Euros
    06:16 Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
    07:06 Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
    07:50 Looking ahead
    08:31 SOZO Intuition

    SUMMARY
    Welcome to today's biotech daily briefing. Today, we lead with positive mid-stage clinical proof-of-concept data from Rapport Therapeutics in acute bipolar mania, expansive platform trial results from Arcus Biosciences evaluating casdatifan across multiple lines of clear cell renal cell carcinoma, and long-term extension data from Teva and Sanofi demonstrating sustained efficacy for duvakitug in inflammatory bowel disease. We also follow regulatory and clinical advancements spanning biomanufacturing, rare disease acquisitions, critical care respiratory medicine, and gastrointestinal oncology. Sources are in the show notes.

    CHAPTERS AND SOURCES

    00:00 - Biotech Daily Briefing

    00:43 - RAP-219 Meets Primary Endpoint in Acute Bipolar Mania
    Rapport Therapeutics Reports Positive Phase 2 Results for RAP-219 in Bipolar Mania 2026-10-20:
    https://www.sec.gov/Archives/edgar/data/2012593/000119312526425647/d185134dex991.htm
    PolarityBio Phase 3 COVER DFUS II Meets Primary Endpoint in Diabetic Foot Ulcers 2026-10-20:
    https://www.biospace.com/press-releases/polaritybio-highlights-highest-scoring-abstract-award-and-presentation-of-phase-3-cover-dfus-ii-trial-results-at-sawc-fall-2026

    01:32 - RAP-219 Validates Selective Mechanism in Acute Mania

    02:12 - Casdatifan Shows Efficacy in Renal Cell Carcinoma
    Arcus Biosciences Presents ARC-20 Data for Casdatifan Across ccRCC Lines 2026-10-20:
    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000047/rcus-20261020.htm

    03:02 - Casdatifan Delivers 35-Month Median Overall Survival

    03:46 - Duvakitug Sustains Efficacy in Inflammatory Bowel Disease
    Teva and Sanofi Report 44-Week Phase 2b Data for Duvakitug in IBD 2026-10-20:
    https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/UEG-Week-Teva-and-Sanofis-Duvakitug-Maintained-Long-Term-Positive-Outcomes-in-New-Phase-2b-Data-for-Ulcerative-Colitis-and-Crohns-Disease/default.aspx
    Odyssey Therapeutics Reports Phase 2a OD-001 Data in Ulcerative Colitis 2026-10-20:
    https://www.sec.gov/Archives/edgar/data/1882782/000119312526425684/odtx-ex99_1.htm

    04:43 - FDA Approves Process 2.0 for Alvotech's SIMLANDI
    Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process 2026-10-20:
    https://www.biospace.com/press-releases/alvotech-receives-fda-approval-for-new-simlandi-manufacturing-process-that-more-than-doubles-output-per-batch

    05:27 - Ambrose Acquires AM-Pharma for up to 161 Million Euros
    Ambrose Healthcare Acquires AM-Pharma for Up to €161 Million 2026-10-20:
    https://www.biospace.com/press-releases/ambrose-healthcare-acquires-am-pharma-for-up-to-161-million-expanding-its-rare-disease-pipeline-and-gaining-a-european-base

    06:16 - Inhaled EXO-CD24 Meets Primary Endpoint in Mid-Stage Trial
    Nano24 Reports Positive Phase 2b Results for Inhaled EXO-CD24 in ARDS 2026-10-20:
    https://www.businesswire.com/news/home/20261020667516/en/Nano24-Reports-Positive-Phase-2b-Results-for-Inhaled-EXO-CD24-in-Acute-Respiratory-Distress-Syndrome-ARDS-at-the-CHEST-Annual-Meeting-2026

    07:06 - Phase 3 RELIGHT Data for Retlirafusp Alfa in Gastric
    Hengrui's Retlirafusp Alfa RELIGHT Phase 3 Results Published in JCO 2026-10-20:
    https://www.hengrui.com/media/detail-1054.html

    07:50 - Looking ahead
    AstraZeneca and Oracle Launch Global AI Collaboration for Clinical Trial Optimisation 2026-10-20:
    https://www.astrazeneca.com/media-centre/press-releases/2026/astrazeneca-oracle-launch-global-ai-collaboration-advance-clinical-trial-optimisation-support-better-patient-outcomes.html
    Adocia Raises €7 Million and Extends Cash Runway to 2028 2026-10-20:
    https://www.adocia.com/composants/uploads/2026/10/ADOCIA-PR-FINANCING-OPERATION-OCTOBER-2026.pdf

    08:31 - SOZO Intuition

    9 min
  • Biotech Daily - Oct 16th, 2026

    Daily - Oct 16, 2026 - Show Notes

    Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
    https://sozointuition.com

    CHAPTERS
    00:00 Today's Biotech Brief Lead Stories
    00:42 FDA Approves Roche's Enspryng for Thyroid Eye Disease
    01:17 Enspryng Clinical Profile and SatraGO-2 Efficacy
    02:03 Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
    02:39 Revita Significantly Reduces Post-GLP-1 Weight Regain
    03:26 Mankind Pharma Acquires Majority in Armed Cell
    03:56 Armed Cell Platform and Strategic Leadership
    04:39 Regulatory Moves: Zilbrysq Autoinjector and Talvey
    05:49 Financings and M&A: City Therapeutics and Samsung
    06:48 Looking ahead
    07:36 SOZO Intuition Platform

    SUMMARY

    CHAPTERS AND SOURCES

    00:00 - Today's Biotech Brief Lead Stories

    00:42 - FDA Approves Roche's Enspryng for Thyroid Eye Disease
    FDA approves Roche's Enspryng satralizumab, a first-in-class IL-6R inhibitor, as the first at-home subcutaneous treatment for thyroid eye disease 2026-10-16:
    https://www.roche.com/media/releases/med-cor-2026-10-16

    01:17 - Enspryng Clinical Profile and SatraGO-2 Efficacy

    02:03 - Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
    Fractyl Health reports that Revita met the six-month co-primary endpoint in the pivotal REMAIN-1 study, cutting weight regain after GLP-1 discontinuation…:
    https://www.globenewswire.com/news-release/2026/10/16/3382499/0/en/fractyl-health-s-revita-meets-six-month-co-primary-endpoint-in-ongoing-remain-1-pivotal-study-with-highly-statistically-significant-reduction-in-weight-regain-after-glp-1-discontin.html
    Opus Genetics presents positive clinical data from the OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 2026-10-16:
    https://ir.opusgtx.com/press-releases/detail/545/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-

    02:39 - Revita Significantly Reduces Post-GLP-1 Weight Regain

    03:26 - Mankind Pharma Acquires Majority in Armed Cell
    Mankind Pharma enters CAR-T with a EUR 48 million deal for a 70% stake in Belgium's Armed Cell Therapeutics 2026-10-16:
    https://www.mankindpharma.com/media/press-release/mankind-pharma-to-acquire-majority-stake-in-armed-cell-therapeutics-marking-strategic-entry-into-next-generation-car-t-therapies/

    03:56 - Armed Cell Platform and Strategic Leadership
    Acepodia receives TFDA IND approval for ACE723, expanding clinical development to the United States, China and Taiwan 2026-10-16:
    https://www.acepodia.com/newsroom-detail/ACE723_IND_TW/

    04:39 - Regulatory Moves: Zilbrysq Autoinjector and Talvey
    UCB receives U.S. FDA approval for ZILBRYSQ zilucoplan autoinjector self-administration in generalised myasthenia gravis 2026-10-16:
    https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-for-zilbrysqr-zilucoplan-autoinjector-self-administration-for-adults-living-with-generalized-myasthenia-gravis
    CHMP recommends approval of Johnson & Johnson's TALVEY talquetamab plus daratumumab in earlier-line relapsed or refractory multiple myeloma 2026-10-16:
    https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma

    05:49 - Financings and M&A: City Therapeutics and Samsung
    Samsung Biologics publishes the definitive interim result of its tender offer for PolyPeptide with an 87.92% participation rate 2026-10-16:
    https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-definitive-interim-result-for-polypeptide-tender-offer
    City Therapeutics raises $200 million in an upsized initial public offering, the largest biotech IPO pricing of the week 2026-10-16:
    https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html
    Soufflé Therapeutics raises an oversubscribed $135 million Series B to advance its RNA delivery platform 2026-10-16:
    https://www.citybiz.co/article/919851/souffle-therapeutics-raises-135m-to-advance-rna-delivery-platform/

    06:48 - Looking ahead
    Shareholders of Indivior and Supernus Pharmaceuticals approve their all-stock merger of equals 2026-10-16:
    https://www.indivior.com/latest/category/company-statements/2026/indivior-shareholders-approve-proposed-merger-with-supernus
    Edesa Biotech receives FDA IND clearance for a Phase 2 study of EB06 in vitiligo 2026-10-16:
    https://www.biospace.com/press-releases/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study
    Eclipse Life Sciences reports positive Phase 2 BETTIS-1 topline results for EC-104 in diabetic macular edema 2026-10-16:
    https://www.globenewswire.com/news-release/2026/10/15/3381495/0/en/eclipse-life-sciences-announces-positive-topline-results-from-phase-2-bettis-1-study-evaluating-ec-104-for-diabetic-macular-edema-dme.html
    Additional references omitted to fit YouTube's 5,000-character limit.

    8 min
  • Biotech Daily - 15th October 2026

    This digest covers key developments from AstraZeneca, insitro, Takeda, Krystal Biotech, Labcorp Holdings and OMass Therapeutics, including a billion-dollar AI target-discovery collaboration, the first orexin agonist launch for narcolepsy type 1, positive early dermatology clinical data in Gorlin syndrome, a $722 million diagnostics asset acquisition, an FDA-accepted NDA resubmission and a $310 million Series C, alongside broader coverage across the sector. 

    This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

    7 min
  • Biotech Daily - 14th October 2026

    This digest covers key developments from Zealand Pharma, Arrowhead Pharmaceuticals, Pharming, Galderma, and Alentis Therapeutics, including a billion-dollar AI-designed protein collaboration, first-in-human tau knockdown data, a positive Phase II immunology readout, and a $1.5 billion dermatology acquisition, alongside broader coverage across the sector. 

    This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

    8 min
  • Biotech Daily - 13th October 2026

    This digest covers key developments from BioNTech, Samsung Biologics, Johnson & Johnson, and Formycon, including Phase III readouts, a cross-border tender offer, and regulatory acceptances, alongside broader coverage across the sector. 

    This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

    7 min

About Biotech Intuition

From the publisher's feed

Biotech Intuition helps you understand the biotechnology developments that matter—without the noise. Each concise episode highlights the day’s most consequential clinical results, regulatory decisions, scientific advances, partnerships, financings, and industry developments. We explain what happened, why it matters, the important uncertainties, and what to watch next.